# A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

> **NCT07241039** · PHASE1 · RECRUITING · sponsor: **AbbVie** · enrollment: 220 (estimated)

## Conditions studied

- Advanced Squamous Tumors

## Interventions

- **DRUG:** ABBV-711
- **DRUG:** Budigalimab

## Key facts

- **NCT ID:** NCT07241039
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2029-04
- **Final completion:** 2030-10
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07241039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07241039, "A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT07241039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*